Nov 24, 2014, 00:00
by
Michael Croft
November 24, 2014 | Last week, the NIH and FDA
proposed measures that would require the release of summary results
of clinical trials for products that are unapproved or unlicensed.
CROs have expressed some concern about the transparency
initiatives, but were mostly positive. Outsourcing-Pharma.com